P515 Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trial

Turner, Dan; Vlamakis, Hera; Marcus, Dana; Yassour, Moran; Bishai, Jason; Yerushalmi, Baruch; Griffiths, Anne M.; Aloi, Marina; Albenberg, Lindsey; Kolho, Kaija-Leena; Abutbul, G; Assa, Amit; Xavier, Ramnik J.; Levine, Arie

doi:10.1093/ecco-jcc/jjx180.642

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small retrospective multicenter study (144) stated that the use of an oral wide-spectrum antibiotic cocktail (including metronidazole, amoxicillin, doxycycline and-in hospitalized patients-also vancomycin) in children with moderate-to-severe UC, refractory to multiple immunosuppressants, was effective in 47% of patients. This cocktail has been further explored in in the pilot PRASCO trial, in which 28 children admitted with ASC were randomized to receiving the oral antibiotic cocktail as an add-on therapy to IVCS (146). Day 5 PUCAI was significantly lower in the antibioticsþIVCS arm versus IVCS alone (25 AE 16.7 vs 40.4 AE 20.4, P ¼ 0.037), meeting the primary outcome of that trial.…”

Section: Antibioticsmentioning

confidence: 99%

Management of Paediatric Ulcerative Colitis, Part 2

Turner

Ruemmele

Orlanski-Meyer

et al. 2018

J. pediatr. gastroenterol. nutr.

190

194

View full text Add to dashboard Cite

show abstract

Section: Antibioticsmentioning

confidence: 99%

Management of Paediatric Ulcerative Colitis, Part 2

Turner

Ruemmele

Orlanski-Meyer

et al. 2018

J. pediatr. gastroenterol. nutr.

190

194

View full text Add to dashboard Cite

show abstract

“…We subsequently published a RCT of the oral antibiotic cocktail, prescribed as an add-on therapy to IVCS in 28 children admitted with ASC. Day 5 PUCAI was significantly lower in the antibiotics + IVCS arm vs. IVCS alone (25±16.7 vs. 40.4±20.4, P=0.037) (140).…”

Section: Induction Of Remission In Active Ulcerative Colitismentioning

confidence: 85%

Antibiotics in inflammatory bowel diseases: do we know what we’re doing?

Ledder

2019

Transl Pediatr

View full text Add to dashboard Cite

Despite the revolution in inflammatory bowel disease (IBD) treatment over the past two decades with the advent of biological therapies, there remains a substantial proportion of patients with inadequate or unsustained response to existent therapies. The overwhelming focus of IBD therapeutics has been targeting mucosal immunity, however with the developing evidence base pointing to the role of gut microbes in the inflammatory process, renewed focus should be placed on the impact of manipulating the microbiome in IBD management. This review provides an overview of the evidence implicating bacteria in the pathogenesis of gut inflammation in IBD and provides an overview of the evidence of antibiotics in IBD treatment. We also suggest a potential role of antibiotics in clinical practice based on available evidence and clinical experience.

show abstract